Shares of Teva Pharmaceutical Industries Limited (TEVA) Sees Large Outflow of Money

Teva Pharmaceutical Industries Limited (TEVA) : The total money flow in Teva Pharmaceutical Industries Limited (TEVA) was negative ($42.09 million), showing the domination of sellers in the Thursday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $80.26 million. Transactions on upticks were comparatively lower at $38.17 million. The uptick to downtick ratio was 0.48. The total block trades done on upticks were valued at $14.08 million. The total block trades on downticks were valued at $57.05 million. The uptick to the downtick ratio of block trades was 0.25. The money flow during block trades was negative ($42.98 million) when the stock traded with a gain of $21 cent. Teva Pharmaceutical Industries Limited (TEVA) was $50.52, an increase of 0.42% over the previous days close.


Teva Pharmaceutical Industries Limited (TEVA) : The highest short term price target forecast on Teva Pharmaceutical Industries Limited (TEVA) is $100 and the lowest target price is $58. A total of 18 equity analysts are currently covering the company. The average price of all the analysts is $74.3 with a standard deviation of $9.29. The stock has recorded a 20-day Moving Average of 1.71% and the 50-Day Moving Average is 2.94%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.35 and $50.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $50.70. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.52, notching a gain of 0.42% for the day. The total traded volume was 5,794,347 . The stock had closed at $50.31 on the previous day.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *